Five-Year Review of China's Administrative Adjudication Mechanism for Early Resolution of Drug Patent Disputes

WISECODE Take

Many biopharmaceutical companies mistakenly believe China's administrative adjudication for early resolution of drug patent disputes is merely regulatory signaling. In reality, it has become a critical front line between generic and brand-name drugmakers prior to market entry. Under Article 76 of China's Patent Law and the Implementation Measures enacted in July 2021, the CNIPA accepted 400 adjudication cases through August 2026, with an average trial period of 180 days—well below the 9-month stay period. Key rulings, such as the Edoxaban Tosilate Tablets series, demonstrate how authorities use administrative rulings to resolve crystal form patents and infringement defenses before launch. Pharma companies entering China must align patent declarations and technical comparisons during registration or risk being blocked prior to drug approval. Companies outside pharma or not targeting China remain unaffected; Chidian offers patent portfolio health checks to help biotech firms map potential barriers in advance. Firms should adopt two actions: First, brand-name drugmakers must accurately record patent scopes on the registration platform to secure stay-period protection. Second, generic manufacturers should review invalidation proceedings before filing to leverage withdrawal mechanisms after oral hearings and reduce litigation costs. The outcome of pharmaceutical patent disputes is no longer decided in post-launch marketing, but in the precision of patent strategy during drug regulatory approval.